"Companion diagnostics": has their time come and gone? - Wikidata - wikimedia - TriplyDB

"Companion diagnostics": has their time come and gone?

"Companion diagnostics": has their time come and gone?

http://www.wikidata.org/entity/Q34135548

about

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein An appraisal of drug development timelines in the Era of precision oncology.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?The anaplastic lymphoma kinase testing conundrum.

P2860

Q26992272-A40E67E0-0F0B-4357-99B4-05E3BE186749 Q35747784-56C100CB-2157-4919-A36B-BDAED8A1CECD Q37619700-5EC897A0-EE49-48B9-9A79-9F7CE906FEAD Q38584379-37277D1C-6ABA-41FD-B710-923D85D8B241 Q38774259-04F3282B-5A34-4B07-AF0B-B2BE9F940F9B Q47911980-C26BD722-AD40-40D0-939B-98CF9ABE00C3 Q48620065-B2F71309-6624-41A1-94DF-E15F7F5CD63B Q53078133-864D420B-545C-44E9-850C-B16E87182838

P2860

"Companion diagnostics": has their time come and gone?

http://www.wikidata.org/entity/Q34135548

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

"Companion diagnostics": has their time come and gone?

@ast

"Companion diagnostics": has their time come and gone?

@en

"Companion diagnostics": has their time come and gone?

@nl

type

label

"Companion diagnostics": has their time come and gone?

@ast

"Companion diagnostics": has their time come and gone?

@en

"Companion diagnostics": has their time come and gone?

@nl

prefLabel

"Companion diagnostics": has their time come and gone?

@ast

"Companion diagnostics": has their time come and gone?

@en

"Companion diagnostics": has their time come and gone?

@nl

P1433

Q34135548-B937AFBC-79A4-4B15-B778-DA5AE0D314E7

P1476

Q34135548-656B32E2-B056-494C-A527-29615379727B

P2093

Q34135548-3CB801D0-97FB-4AAF-95A9-2AC769967981

Q34135548-93B5776F-757F-4522-996F-CC7714889173

P2860

Q34135548-112A1531-A584-4FC2-93FF-7642D7DC7D86

Q34135548-23ED0BAD-E8FC-4E9D-8AFF-D490BD233E68

Q34135548-473A51DD-D6E4-4F2C-ADD2-8AC447F83FDB

Q34135548-4A5D4B54-9FAF-44EF-B083-D428BDEB82B1

Q34135548-5B7870B3-5B90-49C2-990A-7B7F7D95B516

Q34135548-62469158-96E0-4F86-98F0-BA3B10613470

Q34135548-82FD72B7-F48D-4363-847C-6B8A06841291

Q34135548-E57346DB-29A8-4B73-AF78-2579BFE0D506

P304

Q34135548-E3477C6D-DAFA-482B-80C8-FCFECA52CAAC

P31

Q34135548-A066C82B-E23B-4797-8E28-CC13C64D3A51

P356

Q34135548-A48A3C4F-D741-4B1D-A817-ACD9C903854B

P407

Q34135548-1D666D3E-FF50-4C45-B4D1-07844F362028

P433

Q34135548-31C54082-0360-47DA-A594-E0E403F9927F

P478

Q34135548-C40AD46A-456E-43CA-B213-2A31FF69F73E

P50

Q34135548-C5164B0E-1351-4A75-9036-E4ABDDF555AF

P577

Q34135548-17A9CB84-2C8E-4E27-ABE7-2525C44C72DF

P5875

Q34135548-A70EE636-54AA-4966-A0D1-2EE769B1566B

P698

Q34135548-1895AE4C-3ADF-4B1E-97B6-B6EC215D8171

P932

Q34135548-C3FAEA8D-C998-433C-8690-C24CD9B0D4C6

P356

1078-0432.CCR-14-0932

P1433

Clinical Cancer Research

P1476

"Companion diagnostics": has their time come and gone?

@en

P2093

Fred R Hirsch

http://www.w3.org/2001/XMLSchema#string

Paul A Bunn

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.

An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

P304

4422-4424

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-0932

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264246220

http://www.w3.org/2001/XMLSchema#string

P698

25059519

http://www.w3.org/2001/XMLSchema#string

P932

4155019

http://www.w3.org/2001/XMLSchema#string